[Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*; D012561:Schizophrenia, Childhood / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D013050:Spectrometry, Fluorescence; D013565:Sympatholytics / Q000627:therapeutic use; D013997:Time Factors
D000978:Antiparkinson Agents; D003692:Delayed-Action Preparations; D013565:Sympatholytics; D005476:Fluphenazine
K voprosu ob osobennostiiakh terapevticheskogo deistviia fliufenazin-dekanoata (moditen-depo) pri shizogrenii.